These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 20451413)
21. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Mathew P; Tannir N; Tu SM; Carter CM; Bekele NB; Pagliaro L Cancer Chemother Pharmacol; 2010 Mar; 65(4):811-5. PubMed ID: 20052472 [TBL] [Abstract][Full Text] [Related]
22. A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. Bouman-Wammes EW; van den Berg HP; de Munck L; Beeker A; Smorenburg CH; Vervenne WL; Coenen JLLM; Verheul HMW; Gerritsen WR; Van den Eertwegh AJM Eur J Cancer; 2018 Feb; 90():1-9. PubMed ID: 29268139 [TBL] [Abstract][Full Text] [Related]
24. Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer. Yasufuku T; Shigemura K; Matsumoto O; Arakawa S; Fujisawa M J Infect Chemother; 2010 Jun; 16(3):200-5. PubMed ID: 20221782 [TBL] [Abstract][Full Text] [Related]
25. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368 [TBL] [Abstract][Full Text] [Related]
26. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Giannakakis T; Kakolyris S; Theodoropoulos E; Kouroussis C; Michailakis E; Papadouris S; Tsitoura M; Kalbakis K; Souglakos J; Agelaki S; Vardakis N; Georgoulias V Anticancer Res; 2002; 22(6B):3743-8. PubMed ID: 12552987 [TBL] [Abstract][Full Text] [Related]
27. Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Laack E; Dierlamm T; Knuffmann C; Popp J; Schmied B; Dürk H; Wacker-Backerhaus G; Zeller W; Verpoort K; Fiedler W; Kurt Hossfeld D Lung Cancer; 2002 Jun; 36(3):303-7. PubMed ID: 12009242 [TBL] [Abstract][Full Text] [Related]
28. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557 [TBL] [Abstract][Full Text] [Related]
29. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789 [TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518 [TBL] [Abstract][Full Text] [Related]
31. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB; J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181 [TBL] [Abstract][Full Text] [Related]
32. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. Urakami S; Igawa M; Kikuno N; Yoshino T; Kishi H; Shigeno K; Shiina H J Urol; 2002 Dec; 168(6):2444-50. PubMed ID: 12441936 [TBL] [Abstract][Full Text] [Related]
33. Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. Oh WK; George DJ; Tay MH Clin Prostate Cancer; 2005 Jun; 4(1):61-4. PubMed ID: 15992464 [TBL] [Abstract][Full Text] [Related]
34. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308 [TBL] [Abstract][Full Text] [Related]